Rifampin & Isoniazid Serum Levels: dose is not exposure
Why measure rifampin?
Rifampin drives sterilization and culture conversion, and low peak concentrations are common — including in patients taking every dose. Low rifampin exposure has been associated with slower conversion and worse outcomes, and it is one of the most frequent findings when a slow responder is finally measured. It is also the most powerful enzyme inducer in the regimen: it lowers the exposure of moxifloxacin, many antiretrovirals, azoles, anticoagulants, methadone and more — which is precisely why rifabutin exists as an alternative.
| Clinical setting | What the level informs |
|---|---|
| Slow culture conversion on DOT | Whether the sterilizing drug is actually reaching the target exposure. |
| Diabetes | Associated with lower rifampin exposure — a common, silent cause of slow response. |
| HIV on ART | Interaction management; rifabutin levels when rifampin is not acceptable. |
| Companion drug underperforming (e.g. moxifloxacin) | Induction by rifampin lowers the partner drug — measure both. |
What we measure alongside it
Isoniazid (NAT2 acetylator variability), pyrazinamide (most of the early sterilizing effect), ethambutol (renal clearance, optic toxicity at accumulation), rifabutin, moxifloxacin, linezolid, cycloserine, ethionamide and pretomanid — all by LC-MS/MS in serum.
← TB therapeutic drug monitoring — service overview
FAQ
- Is a low rifampin level common?
- Low peak rifampin concentrations are a recurrent finding in patients who are taking every dose, which is exactly why the level is worth having before a slow response is attributed to resistance.
- Why would you use rifabutin instead of rifampin?
- Because rifampin's enzyme induction can make a co-medication - antiretrovirals in particular - unusable. Rifabutin is the rifamycin alternative in that setting, and its own exposure is interaction-sensitive, which is why we measure it too.
- Does rifampin affect the other TB drugs in the regimen?
- It lowers the exposure of several companion agents, moxifloxacin among them. When a partner drug looks like it is underperforming, measuring both is more informative than measuring either alone.
References
- ATS / CDC / IDSA — Treatment of Drug-Resistant Tuberculosis.
- WHO — Consolidated guidelines on drug-resistant TB treatment (BPaL/BPaLM).
- CDC — TB clinical care.
Reach us — privately
No name needed to ask a question. Text is the fastest way to reach us.
Or send your details below — we will reply by text or email during open hours.